title: Brief Report: HIV-1 gp120 T-Cell Responses Correspond to Infection Outcomes in the Global iPrEx Chemoprophylaxis Trial.
abstract: Association of HIV-1-specific T-cell responses to infection risk in seronegative individuals is controversial. We quantified and phenotypically characterized gp120-specific T-cell responses in HIV-1 exposed, but uninfected subjects enrolled in the global Pre-exposure Prophylaxis Initiative (iPrEx) chemoprophylaxis trial. IFNγ ELISpot responses were detected in 24% of subjects irrespective of infection outcome. HIV-1 gp120 envelope-specific T-cell responses were more uniformly IFN-γ+TNF-α+Mip-1β+ in persistently seronegative subjects relative to subjects who later seroconverted (median frequency of 76.5% and 66.5%, respectively). IFNγ responses targeted the V2 loop for subjects who remained seronegative. HIV-1 gp120 envelope V2 loop-specific CD8 T-cell responses may help to protect against HIV-1 acquisition.
authors.affiliation: *Division of Experimental Medicine, University of California, San Francisco, CA;†Gladstone Institutes, San Francisco, CA;‡Department of Medicine, University of California, San Francisco, CA;§Division of Clinical Immunology and Allergy, University of São Paulo, São Paulo, Brazil; and‖Department of Microbiology, Immunology & Tropical Medicine, George Washington University, Washington, DC.
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Kuebler
authors.forename: Brian I
authors.initials: BI
authors.lastname: Shaw
authors.forename: Kaitlyn S
authors.initials: KS
authors.lastname: Leadabrand
authors.forename: Megha L
authors.initials: ML
authors.lastname: Mehrotra
authors.forename: Robert M
authors.initials: RM
authors.lastname: Grant
authors.forename: Esper G
authors.initials: EG
authors.lastname: Kallás
authors.forename: Douglas F
authors.initials: DF
authors.lastname: Nixon
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D016022:Case-Control Studies; D018890:Chemoprevention; D003430:Cross-Sectional Studies; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D016896:Treatment Outcome
chemical_list: D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120